



SESSION LISTINGS:

FRS Featured Research Session
 LPR Lightning Presentation Round
 PER Perspectives Session
 PL Plenary Session
 DEV Developing Topics

Other activities will take place in the Exhibit Hall, including ASK! sessions and poster presentations.

Sunday, July 16								
	Hall 5	Hall 2	Hall 3	Hall 10	Hall 11	Hall 12	Elicium 2	Other
8 - 8:45 a.m.		LPR: Clinical Manifestations		DEV: LEADS: Scientific advances in Sporadic Early-Onset Alzheimer's Disease	DEV: INTERCEPT-AD: A phase I trial of Aβ oligomer-targeting ACU193 in early Alzheimer's disease	DEV: Developing Topics 1	DEV: Developing Topics 2	
8:45 - 9:15 a.m.								
9:15 - 10:30 a.m.		FRS: Towards clinical implementation of Centiloid quantification: Lessons learned from the AMYPAD consortium	FRS: The complex relationship between APOE and glial cells	PER: New horizons on human postmortem neuropathology	FRS: Alzheimer's disease biomarkers in diverse populations	FRS: The role of early life adversity in cognitive decline and dementia	FRS: Meaningfulness of Clinical Trial Outcomes in Alzheimer's Disease: Translation of Results to Patients	
10:30 - 11:15 a.m.								ASK! with Zaven Khachaturian Award Winner
11:15 a.m. - 12:30 p.m.	PL: Rik Ossenkoppele - Tau PET: towards implementation in trials and clinical practice							
12:30 - 2:15 p.m.								
2:15 - 3:30 p.m.	DEV: Learnings from GRADUATE I & II: Paving the way for future therapeutics in AD	FRS: Clinical applications of tau PET	FRS: T cells in brain aging and neurodegeneration	FRS: Beyond the classics: Revamping our knowledge on human neuropathology in neurodegenerative diseases	FRS: Diversity-informed approaches to dementia care	FRS: Psychosocial and other experiential factors at micro- and meso-levels related to dementia risk from middle into older age	FRS: Maximizing learning and efficiency of clinical trials with data sharing and effective biorepositories	
3:30 - 4:15 p.m.								ASK! Plenary Q&A Session with Rik Ossenkoppele
4:15 - 5:30 p.m.	FRS: NIA-AA Revised Clinical Criteria for Alzheimer's Disease	FRS: Novel insights into tau biology in AD and other tauopathies	FRS: ApoE impact and novel therapeutic modalities in Alzheimer's brain	FRS: Redefining frontiers of neuropathologic changes in aging and neurodegenerative diseases	FRS: Global and equitable study designs in aging research and subsequent research yields and the expansion of the field	FRS: Improving dementia care through technology and digital interventions	FRS: Looking Under the Hood of AD Prevention Trials: Analytic Approaches for Cognitive and Biomarker Outcomes	

Monday, July 17

	Hall 5	Hall 2	Hall 3	Hall 10	Hall 11	Hall 12	Elicium 2	Other
8 - 8:45 a.m.		LPR: Basic Science	LPR: Drug Development	DEV: Sleep and Electrophysiological Changes during the progression of Alzheimer's and related dementia	DEV: Ultra-high field (7T) Brain MRI Findings Across Aging, Alzheimer's Disease and Sequelae of Infection with SARS-CoV-2: the 7T neuroCOVID Consortium	DEV: Developing Topics 3	Next Generation AD/ADRD Clinical Trialist: the IMPACT-AD Forum	
8:45 - 9:15 a.m.								
9:15 - 10:30 a.m.		FRS: Building therapeutic pipeline: Tau related targets and therapy development	FRS: Neuroimmune Function in Neurodegenerative Disease	PER: TDP-43 proteinopathy in neurodegenerative diseases: current understanding of pathobiology and development of therapeutics and diagnostics	FRS: Patient and public involvement in dementia research: Global perspectives	FRS: Hearing loss and dementia: cause, consequence or catalyst?	FRS: Modeling longitudinal cognitive decline in aging and Alzheimer's disease	
10:30 - 11:15 a.m.								ASK! with Lifetime Achievement Award Winner
11:15 a.m. - 12:30 p.m.	PL: Cristian Lasagna-Reeves - Bassoon contributes to tau-seed propagation and neurotoxicity PL: Cynthia Lemere - The Evolving Role of Complement in Alzheimer's Disease							
12:30 - 2:15 p.m.								
2:15 - 3:30 p.m.	DEV: Anti-Amyloid treatment in Asymptomatic Alzheimer's disease (A4) and Longitudinal Evaluation of Amyloid Risk and Neurodegeneration (LEARN) Study Longitudinal Results	FRS: Modeling longitudinal disease processes using amyloid and tau PET	PER: Neurodegeneration and inflammation	FRS: Fluid biomarkers of fronto-temporal dementia, Lewy body disease and TDP-43 proteinopathies	FRS: Successful Recruitment of Underrepresented Groups in AD Studies	FRS: Sensory loss and sleep disturbances in persons with dementia and their care partners	FRS: Psychiatric and neuropsychiatric syndromes	
3:30 - 4:15 p.m.								ASK! Plenary Q&A Session with Cristian Lasagna-Reeves and Cynthia Lemere
4:15 - 5:30 p.m.	DEV: Donanemab in Early Symptomatic Alzheimer's Disease: Efficacy and Safety in TRAILBLAZER-ALZ 2, a Phase 3 Randomized Clinical Trial.	FRS: Novel fluid biomarkers of Alzheimer's disease	FRS: Tracking glial contributions to Alzheimer's disease etiology and progression	FRS: Latest advances and future perspectives in biomarkers for Dementia with Lewy bodies	PER: Addressing the disparities in dementia risk, early detection and care in US Latino populations: Insights from the US Consortium of Aging, Dementia and Latino Studies (CADLAS)	FRS: Sleep and brain health: associations and mechanisms	PER: The interface of cognition and behavior for dementia risk	

Tuesday, July 18

	Hall 5	Hall 2	Hall 3	Hall 10	Hall 11	Hall 12	Elicium 2	Other
8 - 8:45 a.m.		LPR: Dementia Care	LPR: Biomarkers	DEV: Effects of hearing intervention on cognitive decline and brain health: Results of the Aging and Cognitive Health Evaluation in Elders (ACHIEVE) randomized trial	DEV: The U.S. Study to Protect Brain Health through Lifestyle Intervention to Reduce Risk (U.S. POINTER)	DEV: Developing Topics 4	Rare AD presentations in the spotlight	
8:45 - 9:15 a.m.								
9:15 - 10:30 a.m.		PER: Advances in plasma Alzheimer's disease biomarkers	FRS: New horizon therapeutics targeting the immune system in Alzheimer's disease	ECBS: What can we learn from multi-omics?	PER: Dementia care in low- and middle-income countries	FRS: Non-pharmacologic risk reduction strategies for Alzheimer's disease prevention: one size does not fit all?	FRS: Proving the Evidence Base for Nationwide Caregiver Programs: Successes and Challenges	
10:30 - 11:15 a.m.								ASK! with Lifetime Achievement Award Winner
11:15 a.m. - 12:30 p.m.	PL: Marsel Mesulam - The aphasic dementia of Alzheimer's Disease PL: Adesola Ogunniyi - The epidemiology of dementia in Africa							
12:30 - 2:15 p.m.								
2:15 - 3:30 p.m.	EC: Endolysosomal pathways and their importance in neurodegenerative diseases	FRS: Blood-based biomarkers in Alzheimer's disease	FRS: The vascular contribution to Alzheimer's disease pathology and brain structure	FRS: The Alzheimer's Disease Sequencing Project: Recent Advances and Update of Results.	PER: Opportunities and challenges to promote equity in the dementia diagnosis and care in the current landscape of advanced (but less accessible) diagnostic tools and treatment options: The GBHI experience	FRS: New developments in dementia risk prediction scores, profiles and methods	FRS: Cognitive and non-cognitive aspects of dementia	
3:30 - 4:15 p.m.								ASK! Plenary Q&A Session with Marsel Mesulam and Adesola Ogunniyi
4:15 - 5:30 p.m.	Lecanemab: Appropriate Use Recommendations	FRS: Novel methods of detection of α -synuclein pathology and their relevance for Alzheimer's and Lewy body disease research, practice and trials	EC: IS it all in the vessels? Understanding the role of the vascular system in dementia	BS, FRS: Genotype-phenotype insights from atypical Alzheimer's disease	PH, PER: Alzheimer's disease and related dementias (AD/ADRD) research in Low- and Middle-Income Countries (LMICs)	PH, FRS: Non-pharmacological interventions and lifestyle changes to prevent cognitive decline and dementia	FRS: Dyadic patterns of subjective cognitive change: Addressing key knowledge gaps to facilitate ADRD research along the early disease continuum	

Wednesday, July 19

	Hall 5	Hall 2	Hall 3	Hall 10	Hall 11	Hall 12	Elicium 2	Other
8 - 8:45 a.m.		LPR: Public Health	EC: Emerging Concepts in Basic Science: Panel DiscussionI	ALZ-NET: A Real World Data Platform to Inform the Future of Alzheimer's Research, Treatment and Care	Developing Topics 5	Developing Topics 6		
8:45 - 9:15 a.m.								
9:15 - 10:30 a.m.		FRS: Incidence, pathogenesis, and clinical implications of amyloid related imaging abnormalities (ARIA)	FRS: Cerebrovascular features associated with increased APP dosage in Down syndrome and duplication of the APPLocus (DupAPP)	FRS: Multiomics approaches to understanding ADRD development	FRS: Sex and gender specific risk factors for cognitive decline and neurodegeneration	PER: Novel approaches to address caregiver burden and stress	Title TBD: BACE Inhibition	
10:30 - 11:15 a.m.								ASK! with Maria Carrillo
11:15 a.m. - 12:30 p.m.	PL: Rachelle Doody, Michael Irizarry, Jaren Landen, John Sims - Amyloid reduction and evidence of downstream biomarker modification							
12:30 - 2:15 p.m.								
2:15 - 3:30 p.m.	FRS: World Alzheimer Report 2022: Dementia treatment, care and support – are global health systems ready for what's next?	FRS: The role of neuroimaging in the era of anti-amyloid therapies: challenges and opportunities in research and clinical praxis.	PER: Emerging biomarkers for common co-pathologies	FRS: Modern concepts and approaches in polygenic score analysis of Alzheimer's disease	PER: Closing the sex/gender gap in dementia: homing in on the vasculature	FRS: Exploring dementia care best practices and approaches to improve outcomes in a variety of settings and populations	PER: Retinal imaging and its potential role in future clinical practice for Alzheimer's disease	
3:30 - 4:15 p.m.								ASK! with Blas Frangione Award Winner
4:15 - 5:30 p.m.	FRS: Implementation of plasma AD biomarkers in diverse community-based and primary care settings	FRS: Imaging brain connectivity and function	FRS: The selective vulnerability of the neuromodulatory subcortical systems: mechanisms underlying Alzheimer's disease risk	FRS: Novel GWAS approaches in ADRD	FRS: Clinical and neuroimaging correlates of neuropathologic changes: roles of age, sex and comorbidities	PER: Patient Access to Treatments for Alzheimer's Disease in the US and EU: A Comparative Public Policy Perspective	PER: International Centers for Alzheimer Research: key players for research, education and societal outreach of Alzheimer's disease	

Thursday, July 20

	Hall 5	Hall 2	Hall 3	Hall 10	Hall 11	Hall 12	Elicium 2	Other
8 - 9:15 a.m.		FRS: New clinical candidates and learnings from anti-amyloid therapeutic trials	FRS: The complex relationship between TBI and ADRD	FRS: Proteins for profiling and understanding Alzheimer's disease	FRS: Metabolic and hormonal connections to AD	FRS: Modifiable risk factors and multimorbidities in dementia	FRS: Advancement of human cell-based Alzheimer's disease modeling	
9:15 - 9:45 a.m.								
9:45 - 11:00 a.m.	PL: Ana Quiñones - An agenda for addressing multimorbidity and racial and ethnic disparities PL: Goldie Byrd - Inclusion in research and clinical trials							
11:00 - 11:30 a.m.								ASK/ Plenary Q&A Session with Ana Quiñones and Goldie Byrd
11:30 a.m. - 12:45 p.m.	FRS: The prognostic utility of blood-based biomarkers	FRS: The neurophysiology of AD: experimental insights and clinical treatments	FRS: Imaging in fronto-temporal dementia, LATE and chronic traumatic encephalopathy	FRS: Integrating genetics, biomarkers and endophenotypes in mice and humans	FRS: Metabolic and systemic diseases: Associations with dementia and cognition	FRS: Preclinical therapeutic targets and early phase studies	PER: Highlights of the Alzheimer's Association International Conference (in Dutch)	